Seelos Therapeutics to Participate in Upcoming Investor Conferences in December

NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3rd in Boston, MA, and the Benchmark Company Discovery One-on-One Conference on Wednesday, December 4th in New York, NY.

About Seelos Therapeutics:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases.
Seelos is based in New York, New York.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
[email protected]   
www.seelostherapeutics.com  
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

You May Also Be Interested In

• Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
• Ethereum Price Prediction: ETH Could Jump 24% to $3,050 as AlphaPepe Gives Retail a 34x Path to $1
• Building Global Trust in the AI Search Era: DigiMentumPR Explores the Future of PR for Technology Brands